What is the difference between semaglutide and tirzepatide?
Semaglutide (Wegovy) is a single GLP-1 receptor agonist: it slows gastric emptying, improves glucose control, and reduces appetite. Tirzepatide (Zepbound) is a dual GIP/GLP-1 receptor agonist — it activates a second pathway (GIP) that amplifies the weight-loss effect. Clinical trials show the dual agonist produces greater average weight loss, which is why it's often the first choice in Evansville when cost allows. Most people who read this are comparing questions to ask your GLP-1 provider before signing up options around Evansville, IN, so what follows sticks to the details that change in practice.
Why is the 3-4 month evaluation the clinical standard?
Both medications must be assessed at 3 to 4 months to decide on dosage adjustments or a medication switch. Individual response varies widely — some patients need a higher dose, some respond better to the other agent. The evaluation is the checkpoint that keeps treatment on track.
The short version
- Semaglutide, branded Wegovy, is described as a single GLP-1 receptor agonist that slows gastric emptying, improves glucose control and reduces appetite.
- Tirzepatide, branded Zepbound, is a dual GIP and GLP-1 receptor agonist activating a second pathway that amplifies weight loss, which trials show produces greater average loss.
- Both medications are to be assessed at 3 to 4 months to decide on dose adjustments or a switch, because individual response varies widely between patients.
- FDA guidelines are said to require pairing pharmacotherapy with a comprehensive lifestyle intervention to preserve skeletal muscle and support long-term metabolic health.
- Protein intake of 1.2-1.6 g/kg plus resistance training is given as the signal for muscle retention, without which a meaningful share of weight lost can be lean mass.
- The article warns that without maintenance planning weight regain is common, citing maintainers' habits of daily weighing, high activity levels and structured meals.
Why must medication be paired with lifestyle intervention?
FDA guidelines require pairing pharmacotherapy with a comprehensive lifestyle intervention (CLI) to preserve skeletal muscle and support long-term metabolic health. The protein-mTOR cascade matters here: adequate protein (1.2-1.6 g/kg) plus resistance training signals muscle retention during the deficit — without it, a meaningful share of weight lost can be lean mass.
What happens when you stop?
Without maintenance planning, weight regain is common — studies of long-term maintainers show that sustained habits (daily weighing, high activity levels, structured meals) are what separate the 11% who keep it off. Programs in Evansville build the maintenance protocol into the plan from day one.
